Ligand Pharma (LGND) Tops Q3 EPS by 116c ; Offers Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $290.07 +2.32%
EPS Growth %: -24.9%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -24.9%
Financial Fact:
Net income (loss):: 1.05M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $3.09, $1.16 better than the analyst estimate of $1.93. Revenue for the quarter came in at $115.46 million versus the consensus estimate of $57.22 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $7.40-$7.65, versus the consensus of $6.87. Ligand Pharma sees FY2025 revenue of $225-235 million, versus the consensus of $212.8 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- GM Defense wins $697.7 million Army contract modification
- Vicor raises Q3 2026 revenue guidance on new licensing deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
